Dr. Dimartino is a Lecturer at the Institute for Bioengineering at the University of Edinburgh, UK. He has been always working, in a way or in another, in the development of new stationary phases for chromatography. He did his PhD at the University of Bologna on membrane chromatography, followed by a postdoc on monolithic stationary phases. He then moved to the University of Christchurch, New Zealand, where he initially studied fibre-based media for bioseparations. Eventually, together with Prof. Fee, he started employing 3D printing methods for the fabrication of chromatography media with perfectly ordered internal morphology. This research, regarded as completely novel on a global basis, has granted him and the wider research group with a number of international awards, including 3 best poster awards in 3 continuous years at the PREP conferDr Rodney Rietze is a Senior Investigator in the Exploratory Immuno-Oncology group at the Novartis Institutes for Biomedical Research (Cambridge, MA) developing novel bioprocesses and enabling technologies for the manufacture of next-generation CAR-T therapeutics. This role is a continuation of his work at Novartis’s Cell and Gene Therapy Unit, where he lead the Automation Network supporting the manufacturing process and analytics for Kymriah, the first FDA-approved personalized CAR-T cell therapy. Before joining Novartis, Dr Rietze was a Senior Director of Process Development for Ovasave at TxCell S.A. (France) and led teams in the discovery and early clinical development of both small molecule and cell-based therapeutics at Pfizer Regenerative Medicine (Cambridge, UK). Preceding his transition to Industry, Dr Rietze was a co-founder and faculty member of the Queensland Brain Institute (Brisbane, Australia). Dr Rietze has nearly two decades of technical, operational and strategic leadership experience in the development of cell-based therapies and is passionate about delivering innovative technologies and medicines to transform the treatment of disease. He holds a BSc and MSc from the University of Calgary, and a PhD from The University of Melbourne (Australia).nce series, and the Csaba Horvath Young Scientist Award at HPLC 2016.
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.